(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 November 2022 (17.11.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/240978 A8

(51) International Patent Classification:
C07D 498/22 (2006.01) *A61K 31/395* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2022/028755

(22) International Filing Date:
11 May 2022 (11.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/187,041 11 May 2021 (11.05.2021) US

(71) Applicant: **THESEUS PHARMACEUTICALS, INC.** [US/US]; 245 Main Street, 2nd Floor, Cambridge, MA 02142 (US).

(72) Inventors: **HUANG, Wei-Sheng**; c/o Theseus Pharmaceuticals, Inc., 245 Main Street, 2nd Floor, Cambridge, MA 02142 (US). **SHAKESPEARE, William, C.**; c/o Theseus Pharmaceuticals, Inc., 245 Main Street, 2nd Floor, Cambridge, MA 02142 (US). **EYERMANN, Charles, J.**; c/o Theseus Pharmaceuticals, Inc., 245 Main Street, 2nd Floor, Cambridge, MA 02142 (US). **DALGARNO, David, C.**; c/o Theseus Pharmaceuticals, Inc., 245 Main Street, 2nd Floor, Cambridge, MA 02142 (US).

(74) Agent: **COLES, Anthony** et al.; Proskauer Rose LLP, One International Place, Boston, MA 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:
05 October 2023 (05.10.2023)

(15) Information about Correction:
see Notice of 05 October 2023 (05.10.2023)

(54) Title: MACROCYCLIC COMPOUNDS AND USES THEREOF



(I)

(57) Abstract: Described herein are macrocyclic compounds of Formula (I), which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a compound of Formula (I), or any pharmaceutically acceptable form thereof, processes for their preparation, and use in therapy for the prevention or treatment of cancer. In particular, compounds described herein can be effective for treating EGFR-driven cancers including non-small cell lung cancer (NSCLC).

WO 2022/240978 A8